Primitive neuroectodermal tumors of the central nervous system (CNS-PNETs) are a class of malignant childhood brain tumors featuring poorly differentiated cells of neural origin. Among these, tumors that fall under the histologic category of embryonal tumor with multilayered rosettes (ETMR) (first described as "embryonal tumor with abundant neuropil and true rosettes" or ETANTR) occur primarily in infants and young children and are particularly aggressive, with typical survival of ,1 year after diagnosis despite intensive therapy. 1, 2 Recently, ETMRs have been found to harbor recurrent focal amplifications of chr19q13.41-42, encoding the large polycistronic microRNA cluster C19MC, a genetically defining lesion that is likely critical to the biology of the disease. 3, 4 Amplification of C19MC is associated with marked overexpression of miRNAs in the cluster that can drive proliferation, promote survival, and increase tumorigenicity of cells. 3 The oncogenic properties of the overexpressed miRNAs reflect some of the known functions of C19MC. In normal development, the C19MC locus is posited to control general "stemness" programs, as many C19MC miRNAs show expression restricted to undifferentiated tissues or germinal tissues, and their expression decreases with human embryonic stem cell differentiation. 5 -7 Further supporting the association of C19MC with stemness, the pluripotency-associated transcription factors Oct4 and Nanog may regulate C19MC miRNAs in human embryonic stem cells. 5 Interestingly, C19MC-amplified CNS-PNETs also show striking upregulation of other distinctive primitive markers including the RNA-binding proteins Lin28A and LIN28B, 8 a finding that is diagnostically useful as a marker of ETMRs. 9 Beyond its diagnostic utility, however, Lin28 overexpression may be functionally important as well. Through binding and repression of let-7 microRNAs, Lin28 has been found to regulate lineage, stemness, cellular metabolism,and the cell cycle in normal and disease states. 10 -12 Lin28 also directly binds other mRNAs to increase their translation, with the cumulative effect that Lin28 may coordinately control both proliferative growth and metabolism. 13 -19 Despite our increasing knowledge of C19MC and Lin28 functions, the biology of ETMR has remained poorly understood. Furthermore, the ability to translate the molecular findings to potential therapeutic targets for these tumors has been hampered by a lack of model systems for the disease. Here, we have established a patient-derived ETMR cell line that maintains the characteristic genetic and histologic features of the disease including C19MC-amplification and Lin28 expression. We found that Lin28 expression was inversely correlated with expression of let-7 microRNAs and positively associated with mTOR pathway activation. Lin28 knockdown also increased let-7 expression and decreased expression of mTOR signaling pathway components, supporting the notion that Lin28 dysregulation is functionally important in ETMR. This novel cell line will be an important tool for further investigating ETMR biology and for identifying future therapies for this and other C19MC-overexpressing cancers.
Materials and Methods

Tumor and Nucleic Acid Samples
Formalin-fixed paraffin embedded (FFPE) tumor specimens and fresh frozen tumor specimens were collected with consent per protocols approved by the Hospital for Sick Children Research Ethics Board in Toronto and the Conjoint Health Research Ethics Board of the University of Calgary. Clinical and genetic information on these tumors was reported previously. 3 Only tumors classified histologically as CNS-PNET according to 2007 WHO CNS tumor classification criteria 20 were included. DNA and RNA were extracted from frozen tumor material using Qiagen DNeasy (Qiagen) and Trizol (Invitrogen), respectively, per manufacturer's protocol. In this paper, we use a genetic definition of ETMR to refer to histologic CNS-PNETs (including those that have a variety of described histologic patterns including but not restricted to CNS-PNET NOS, ETANTR, medulloepithelioma, and ependymoblastoma) that carry C19MC amplification.
Cell Culture
Fresh tumor tissue was dissociated by gentle manual trituration followed by passage through a 40 mm mesh filter. Cells were grown in low-adhesion tissue culture flasks (Sarstedt) in defined serum-free media at 378C, 5% CO 2 . Initial culture media consisted of human neural stem cell proliferation media (Stem Cell Technologies) supplemented with heparin, epidermal growth factor (EGF; 20 ng/mL; Peprotech), fibroblast growth factor (FGF; 20 ng/mL; Peprotech), and sonic hedgehog (recombinant human SHH, 0.1 mg/mL; R&D Systems)×2 weeks. The cells were subsequently maintained in the same media without SHH. Cells were fed every 3 -4 days. After 1 week in initial culture, small aggregates were apparent. At 2 weeks, well-formed tumor neurospheres were present. When tumorspheres were 100-200 mm in diameter, cells were split using Accumax (Millipore) and manual trituration, and replated at a density of 20 000 cells/mL. After 10 consecutive passages, the cell line was designated BT-183-AB (BT183). For differentiation assays, cells were grown for 7 days in the media as above, supplemented with 1% fetal bovine serum and without additional EGF or FGF.
Orthotopic Xenografts
Tumorsphere cultures were dissociated into single cells and resuspended in sterile phosphate-buffered saline. One hundred thousand viable cells in a volume of 3 ml were implanted into the right striatum of 6-8 week old CB-17 NOD-SCID mice (Jackson Labs) using the following stereotactic coordinates: -1.0 AP, 2.0 ML, 3.0 DV. Mice were euthanized and their brains harvested at 8 weeks for histologic examination and isolation of nucleic acids. All animal procedures were approved by the Health Sciences Animal Care Committee at the University of Calgary.
Histology and Immunohistochemistry
For FFPE sections, tissue was fixed in 10% neutral buffered formalin, and processed for paraffin embedding by routine methods. For frozen sections, cells grown in tumorspheres or brain tissue with orthotopic xenografts were fixed in 4% paraformaldehyde in phosphate-buffered saline, cryopreserved in 30% sucrose, and embedded in OCT. 5 mm OCT cryosections; 4 mm FFPE sections were collected on Superfrost Plus slides (VWR). Hematoxylin and eosin staining was performed by routine methods. Immunohistochemistry was performed on FFPE tumor slides. Sections were treated with heat-induced epitope retrieval and blocked for endogenous peroxidase and biotin. The following primary antibodies were used: Lin28 (Cell Signaling Technology), Synaptophysin (Novocastra), b-III-Tubulin (Sigma), Nestin (Thermo Scientific), glial fibrillary acidic protein (GFAP, Dako), Olig2 (Millipore), pAKT(S473) (Cell Signaling Technology), p4EBP1(T37/46) (Cell Signaling Technology), pS6 (S240/244)(Cell Signaling Technology), and pS6 (S235/ 236)(Cell Signaling Technology). Antibody reactivity was visualized with the VectaStain ABC detection kit (Vector Laboratories) or Envision+ DAB system (Dako). Staining was assessed visually on the basis of intensity and distribution of stains. Tissue microarrayspecimens were assessed based on average staining score of at least 2 tissue cores. TS scored all immunohistochemistry stains while masked to cancer status. Scores were reviewed by JC and CEH. Immunofluorescence staining was performed on paraformaldehyde-fixed frozen sections with antibodies as above and detected with Alexa-488 conjugated secondary antibodies (Invitrogen).
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization was performed on individual 5 mm FFPE sections of tumors or tissue microarrays using prelabeled BAC probes (http://www.tcag.ca/cytogenomics) mapping to the chr19q13.42 miRNA cluster (RP11-381E3: 162, 225 bp) and a control chr19p13.11 locus (RP11-451E20: 165,783 bp) as described previously. 3 
Copy Number Analyses
To assess DNA copy number profiles of the C19MC-amplified primary tumor used in this study, we used Illumina Human Omni 2.5 Quad single-nucleotide polymorphism (SNP) array for ultra-high resolution copy number analyses (interrogating 2.5 million SNPs) (Illumina) to generate Spence et al.: Lin28 regulates mTOR pathway in C19MC-amplified ETMR Neuro-OncologyDNA copy number profiles and HapMap samples from Illumina as controls. Copy number profiles were visualized using DNA Chip Analyzer (dChip). Inferred copy number was calculated using median smoothing and a sliding window of 15 SNP probes. For comparison of copy number alterations between primary tumor tissue, BT183 cells, and xenograft tumor tissue, array CGH was performed using 0.5 mg of each DNA sample and human reference DNA (Promega). The genomic DNA from each sample was labeled with Cy5 and co-hybridized with gender matched Cy3-labeled reference DNA on SurePrint G3 Human Catalog CGH 8 ×60 K arrays (Agilent). Arrays were scanned using the Agilent DNA Microarray Scanner, and quantified using Feature Extraction v10.1.1 (Agilent). Normalized CGH signal (log-ratio) was uploaded into Partek Genomics Suite version 6.12 (Partek Incorporated) for visualization and analysis.
MicroRNA Analyses miRNA expression profiles were examined using miRNA Nanostring version1.1 (NanoString Technologies) assessing 654 miRNAs in RNA from 12 primary CNS-PNETs in addition to the parent tumor tissue, established cell line, and xenograft used in this study. Samples were processed per manufacturers' instructions, and miRNA expression data were analyzed by hierarchical clustering analyses using Pearson correlation with average linkage. Taqman quantitative RT-PCR analysis was also performed to confirm overexpression of a specific subset of C19MC miRNAs, downstream miR371-373, and representative let-7 miRNAs using TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems); miRNA expression levels (Ct) determined relative to noncoding RNU6B are represented.
Gene Expression Profiling
Multiple unsupervised hierarchical clustering analyses (genesets of 200-1 000 genes) were performed on human HT-12v4 expression array (Illumina) data from 53 primary CNS-PNETs including the cell line and xenograft used in this study. Gene expression data from the primary CNS-PNETs were reported previously. 3 Cluster patterns were determined using 300 genes with the highest coefficient of variation to establish grouping, using Pearson correlation with average linkage. Gene expression profiles were visualized using Partek Genomics Suite version 6.5 (Partek Incorporated). RNA hybridizations were performed at the Centre of Applied Genomics Facility at the Hospital for Sick Children. Expression levels of the following individual genes were also assayed by Taqman quantitative RT-PCR gene expression assays (Applied Biosystems): LIN28A, LIN28B, RPS6, RHEB, IGFBP2. Expression levels of individual transcripts were determined relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Lin28 Knockdown
Neurospheres were disaggregated to single-cell suspension using Accumax and plated in human neural stem cell proliferation media with EGF and FGF at a density of 50 000 cells/mL in 6-well plates. A mix of siRNAs targeting Lin28 (OnTarget Plus SMARTpool L-028584-01; Thermo Scientific) was transiently transfected into cells using Lipofectamine 2000 (Invitrogen) per manufacturer's protocol at final siRNA concentration of 40 nM in a total transfection volume of 2 mL per well. Cells were harvested at 7 days posttransfection for RNA extraction and analysis by quantitative RT-PCR.
In Vitro Chemosensitivity Testing
Cells were cultured in 96-well plates (5 ×10 3 cells/well) and incubated with 1 mM concentration of the drugs listed in Supplemental Table 1 and as reported previously. 21 All targeted therapeutic agents used in the screening analysis were synthesized, checked for purity, and provided by Chemietek (Minneapolis, MN). These agents were dissolved in dimethyl sulfoxide (DMSO) to a final concentration of 10 mM, stored frozen at -208C, and diluted appropriately in culture medium at the time of study. Each treatment was performed in triplicate. Survival was measured after 4 days in culture and compared with vehicle control using Alamar blue viability assay (Invitrogen) detected in a microplate reader per manufacturer's protocol.
Western Blotting
Western blot analysis and chemiluminescence detection were performed with standard methods for detection using primary antibodies against b-Actin (Santa Cruz Biotechnology), phospho-4EBP1(Thr37/46) (Cell Signaling Technology), pS6(S235/236) (Cell Signaling Technology), and secondary anti-mouse and anti-rabbit HRP conjugated antibodies (Santa Cruz Biotechnology).
Statistical Analyses
For analyses of cell viability and changes in protein expression on Western blots, results were from at least 3 experiments and were analyzed by t test. To assess deregulation of transcripts from gene expression profiling, including LIN28 mRNA and let-7 miRNAs, we assessed gene/miRNA enrichment with a supervised t test adjusted for multiple hypotheses testing with the false-discovery-rate method using R (version R ×64 2.15.2). A P value of ,.05 was regarded as significant for all analyses.
Results
Establishment of Cell Cultures from an ETMR
We used tumor tissue from a 2-year-old male with a known C19MC-amplified posterior fossa ETMR (Figs. 1 and 2 ) to prepare primary cell cultures and then propagated the cells to develop a stable cell line referred to as BT183. These cells formed nonadherent neurospheres within 10 days of initial culture when grown in in serum-free defined media (Fig. 1A) .
Brain tumor stem-like cells derived from some medulloblastoma and glioblastoma tumors expressed stem cell surface markers such as the cell surface markers CD133, CD15, or both, and the intermediate filament nestin. 22 -25 We found that BT183 tumorspheres were negative for CD15 and had only rare cells positive for CD133 but showed strong expression of the neural stem/ progenitor marker nestin 26 in the majority of cells (Fig. 1A) . With regard to lineage markers, BT183 tumorspheres contained only scattered cells expressing the neuronal marker b-III-tubulin, the oligodendroglial lineage marker Olig2, or the astrocytic marker GFAP. Individual BT183 tumorspheres could be dissociated to single cells and then replated in media to generate secondary spheres. Furthermore, when grown in differentiation media, BT183 cells attach to the tissue culture plate and extended processes (Fig. 1B) . These morphologically differentiated cells predominantly expressed the neuronal b-III-tubulin, with rare cells expressing Olig2 or GFAP (Fig. 1 and data not shown) . Together, these findings support that BT183 cells exhibit stem cell-like characteristics but preferentially differentiate along neuronal lineages.
BT183 Cells are Tumor-initiating in Vivo
One of the features of brain tumor stem-like cells is the ability to initiate tumors. To test whether BT183 could generate tumors in vivo, we implanted the cells into the brains of NOD-SCID mice after every 5 passages in vitro. The cells maintained tumorigenicity in mice over 6 subsequent cohorts of mice injected, after which routine Spence et al.: Lin28 regulates mTOR pathway in C19MC-amplified ETMR in vivo propagation was discontinued. The BT183 xenograft tumors bore striking histologic resemblance to the original patient tumor, with sheets of poorly differentiated cells punctuated by welldeveloped multilayered rosettes. (Fig. 2) .
BT183 Cells Harbor Amplification of chr19q13.41
The genetic hallmark of ETMR is high-level amplification of chr19q13.41. 3, 4, 27, 28 To determine the genetic features of our newly established cell line, we analyzed the parent tumor, the cell line, and xenograft tumors using several methods. Highresolution SNP array confirmed the chr19q13.41 amplification in the parent tumor tissue with amplicon boundaries from rs4803149 to SNP19-59570640, inclusive (Fig. 3A) . Fluorescence in situ hybridization showed chr19q13.41 amplification in both the parent tumor, and xenograft (Fig. 3B) . Furthermore, array CGH showed relative similarity between the parent tumor, cell line, and xenograft with respect to genome-wide copy number alterations. These included focal amplification of 19q13.41, as expected, but additionally revealed the presence of several large 
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Neuro-Oncology Spence et al.: Lin28 regulates mTOR pathway in C19MC-amplified ETMR segmental and whole arm or whole chromosome gains or losses at chromosomes 2(+), 7(+), 6q(2), and regions of 1 and 19 (Fig. 3C) . Collectively, these data indicate that BT183 recapitulates the molecular and morphologic features of the parent tumor and represents an important first model for EMTR and related C19MC-amplified or Lin28-overexpressing embryonal brain tumors.
BT183 Cells Show RNA and Protein Expression Characteristic of C19MC-amplified Tumors
C19MC-amplified tumors have distinctive mRNA transcriptional profiles and patterns of protein expression. 3 When assessed relative to the gene expression profiles of a previously reported panel of 53 CNS-PNETs, 3 including 14 others with C19MC amplification and ETMR-compatible histology, unsupervised hierarchical clustering revealed that BT183, its parent tumor, and the xenograft all clustered together and that their transcriptional profiles clustered clearly with the ETMR group and included high expression of LIN28 transcripts (Fig. 4A) . At the protein level, BT183 xenograft tumors showed immunohistochemical similarity to its parent ETMR, with high expression of nestin and Lin28, positivity for Ini1, patchy positivity for synaptophysin, and low expression of GFAP and Olig2 (Fig. 2) , a pattern that is characteristically seen in C19MC-amplified tumors. 3 We previously observed that the pathognomonic C19MC amplification characterizing ETMR is typically accompanied by high expression of miRNAs in the cluster. 3 To test whether BT183 not only retained the DNA level changes but also the associated miRNA profiles, we examined miRNA expression using Nanostring miRNA profiling on the parent tumor, cell line, and xenograft. This global analysis showed that miRNA expression was similar between the three (Fig. 4B) . Expression of specific mature miRNAs Spence et al.: Lin28 regulates mTOR pathway in C19MC-amplified ETMR encoded in the region was also evaluated by miRNA-specific Taqman quantitative RT-PCR. This confirmed high-level expression of C19MC-encoded miRNAs, whereas the miRNAs in the adjacent nonamplified miRNA 371-373 cluster were not highly expressed (Fig. 4C) .
Lin28 Regulates Expression of let-7 miRNAs in C19MC-amplified Tumors
Lin28 proteins are known to regulate stability and/or translation of many different mRNAs 13 -16,17 as well as the processing of noncoding RNAs. With respect to the latter, a key target of Lin28 is the let-7 family of microRNAs. 10 -12 Multiple lines of evidence indicate that each negatively regulates the expression of the other and that together lin28/let-7 acts as a genetic switch wherein expression of either Lin28 or let-7 promotes a stem-like or differentiated state, respectively (reviewed in 29). However the role of Lin28 in ETMR is currently unknown. To explore whether a Lin28/let-7 switch is active in ETMR, we examined the expression of microRNA transcripts relative to expression of LIN28 in our panel of CNSPNETs. We found that high LIN28A and LIN28B expression were inversely correlated with expression of all let-7 miRNA family members ( Fig. 5A and B) . Tumors that harbor C19MC amplification (including BT183 cells, xenograft, and original patient tumor) have uniformly high LIN28 expression and low let-7 expression, whereas the two other major subsets of CNS-PNET show low expression of LIN28 and higher expression of let-7 miRNAs (P , .05 for all comparisons). Furthermore, using a pool of siRNAs, knockdown of LIN28 in BT183 cells resulted in significantly increased expression of representative let-7 family members let-7a (4.34-334% increase change; P ¼ .028) and let-7e (15.25-1425% increase change; P ¼ .019) compared with treatment with nontargeting siRNAs (Fig. 5C  and C) . Together, these findings are consistent with the presence of a functional Lin28/let-7 axis in ETMR.
BT183 Cells and C19MC-amplified Tumors Show Evidence of Lin28-mediated Insulin/PI3K/mTOR Signaling Dysregulation
Aside from controlling proliferation and differentiation, the Lin28/ let-7 axis may also control growth and metabolism through regulation of multiple components of the insulin-PI3K-mTOR pathway. 12, 30 To determine whether human ETMRs have active mTOR pathway signaling, we assessed 5 FFPE patient ETMR Fig. 5 . LIN28 regulates expression of let-7 miRNAs in C19MC-amplified tumors. (A) Heat map of LIN28 and let-7 family gene expression in primary tumor, and BT183 cell line and xenograft using a supervised t test adjusted for multiple testing (false discovery rate ≤0.05); magnitude (fold change) and significance (P value) of genes in C19MC-amplified group in contrast to Groups 2 and 3 CNS-PNETs are shown. LIN28 is inversely correlated with let-7 family miRNAs. (B) Taqman miRNA qRT-PCR on primary CNS-PNETs reveals decreased expression of let-7a, -7b and -7 g in LIN28-positive Group 1 tumors, as compared with Groups 2 and 3 tumors. (C) Knockdown of LIN28 increases expression of let-7a and let-7e miRNAs in BT183 cells compared with treatment with nontargeting control siRNA (*P , .05).
Spence et al.: Lin28 regulates mTOR pathway in C19MC-amplified ETMR samples for expression of phosphorylated-S6 (pS6 S235/236 and S240/244) and phosphorylated 4EBP1 (p4EBP1 Thr37/46) by immunohistochemistry as readouts of pathway activation. We found that all 5 ETMR samples stained positively for both phosphorylated-4EBP1 and phosphorylated-S6 (Fig. 6A and B) consistent with mTOR activation. To then determine whether Lin28 might regulate the insulin/PI3K/mTOR pathway in C19MC-amplified tumors through modulating expression of mTOR pathway components, we performed siRNA knockdown of Lin28 in BT183 cells (Fig. 6C ) and monitored expression of several pathway genes. In our knockdown experiments, LIN28A and LIN28B transcripts were reduced by 60% -70% compared with transfection with nontargeting siRNA control (P , .05). Decreasing LIN28 resulted in both an upregulation of let-7e and let-7a, as described above (Fig. 5C ) and a concomitant decrease in expression of IGFBP2, RHEB, and RPS6 ( Fig. 6C ; P , .05 for each), demonstrating that the Lin28/let-7 axis regulates growth and metabolism signaling components in ETMR.
To determine whether BT183 cells show evidence of a dependence on insulin/PI3K/mTOR signaling, we then treated cells with a panel of 73 pharmacologic inhibitors spanning several classes of targets. BT183 cells showed sensitivity to IGF1R, PI3K, and mTOR inhibition in contrast to little or no sensitivity to a variety of other receptor tyrosine kinase and tyrosine kinase inhibitors (Fig. 7A , Supplemental Table 2 ). In the panel of drugs screened, the only other pharmacologic agents that showed similar responses at 1 mM concentration were more generalized cell cycle or structural directed therapies (eg, topoisomerase inhibitors, tubulin stabilizers, Bcl-2 inhibitors, nucleic acid synthesis inhibitors) that are not targeted at specific signaling pathways. Overall, the data support a role for the Lin28/let-7 axis and signaling through insulin-PI3K-mTOR as an important factor in these tumors' biology. The data further highlight the utility of this line for in vitro screening, and suggest that other types of agents (eg, HDAC inhibitors among others) may also have therapeutic potential in these aggressive tumors.
Discussion
ETMR (now the proposed name for tumors previously called ETANTR) is a recently discerned type of CNS-PNET that is clinicopathologically distinct from other subgroups of CNS-PNETs due to its very young demographic, strikingly poor survival, characteristic histopathology featuring multilayered rosettes, and hallmark amplification of chromosome 19q13.41 that encodes the large microRNA cluster C19MC. We have established and characterized the first known ETMR cell line, BT183. We showed that BT183 harbors the hallmark C19MC amplification, displays transcript and protein expression profiles characteristic of ETMR, and is capable of initiating tumor growth when orthotopically xenografted into mice. Although a small number of CNS-PNET cell lines have been generated and used by others, their C19MC status is either unknown, not reported, or known to be unamplified.
3,31 -33 Furthermore, their histologies and resemblance to specific variants are unclear. As the only cell line derived from a genetically well-documented ETMR, BT183 represents an important tool for further investigation into ETMR and biology and will enable future efforts to find effective therapies for this disease.
Characterization of ETMR using BT183 supports is a role for the RNA-binding protein Lin28. High Lin28a and Lin28b expression has been observed previously in C19MC-amplified PNETs by our group and others, 3, 9 and this expression has been found to be a useful diagnostic tool for distinguishing these ETMR from atypical teratoid rhabdoid tumor, medulloblastoma, anaplastic ependymoma, glioblastoma, and non-ETMR PNETs. 9 However whether Lin28 proteins are simply markers of the primitive cell state in these tumors or serve a more active role in ETMR biology is unknown. In our cell line and panel of tumors, we found that C19MC amplification was not only associated with high LIN28 expression, but also that LIN28 levels were inversely correlated with let-7 microRNA expression. Functionally, Lin28 appears to regulate let-7 levels, as knockdown of LIN28 results in increased let-7 levels. Among other roles, Lin28 proteins can repress let-7 microRNAs, 34 -37 and 
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As emerging evidence indicates that Lin28/let-7 controls insulin-PI3K-mTOR signaling, we also investigated whether ETMRs show evidence of aberrant activation of mTOR. We found expression of both phosphorylated 4EBP1 and phosphorylated S6, supporting that mTOR is indeed activated in these tumors. This was also evident in BT183 cells and xenografts. Furthermore, when we treated BT183 cells with a panel of inhibitors, the cells showed sensitivity to agents targeting IGF1R, PI3K, and mTOR but not to those targeting other receptor tyrosine kinases or intracellular signaling kinases. Beyond corroborating the potential activity of lin28/let-7 in regulating metabolism in these cells, these finding have therapeutic implications as well. Therapies targeting the insulin/mTOR pathway, such as rapamycin and metformin, have already been developed and are in clinical use for other indications. It is possible that these drugs, likely in combination therapy, will have clinical value as therapy for ETMR.
Finally, our small drug screen highlights the utility of our cells for in vitro studies and the identification of potential other classes of drugs that might be investigated for ETMR therapy as well. Our in vitro findings suggest a rationale for differentiating therapies (as exemplified by HDAC inhibitors, valproic acid, or retinoids) in combination with topoisomerase inhibitors (such as etoposide). Some of these drugs are already in clinical trials for pediatric brain tumors (eg, ClinicalTrials.gov Identifiers NCT01294670, NCT00867178, NCT01076530, NCT00994500). Although individual trials are unlikely to have sufficient numbers of ETMR patients from which to draw conclusions for this particular patient subset, the results of these studies will be followed with interest. As is the case with other rare pediatric malignancies, true progress in understanding tumor biology and achieving higher cure rates will require international collaboration.
Overall, our data show that the unique cell line BT183 represents ETMR and will enable further studies aimed at understanding the function of C19MC microRNAs, translational regulation by Lin28, and potential biologic dependencies that may be exploited for therapeutic benefit.
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